Business Context and Reporting Period
Company: NERVGEN PHARMA CORP.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: May 15, 2026
Reporting Period: This filing incorporates by reference interim financial statements and management discussion for the three months ended March 31, 2026.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are located in the incorporated exhibits (Exhibit 99.1 and 99.2) which are not included in the input text.
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or narrative regarding material changes versus the prior comparable period (three months ended March 31, 2025). This information is contained within the incorporated Management's Discussion and Analysis (Exhibit 99.2).
Guidance, Outlook, and Risks
No specific guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided cover sheet text. These disclosures are expected to be found in the incorporated Exhibit 99.2.
Investor Verification Checklist
- Review Exhibit 99.1 for the Condensed Consolidated Interim Financial Statements to verify actual revenue, net loss, and cash position for the quarter ended March 31, 2026.
- Examine Exhibit 99.2 for Management's Discussion and Analysis to understand operational progress, burn rate, and any material changes from the prior year.
- Confirm the status of the Form F-10 and Form S-8 registration statements referenced in the incorporation by reference section.
- Verify the certifications provided by the CEO and CFO in Exhibits 99.3 and 99.4 regarding the accuracy of the interim filings.